© 2020 MJH Life Sciences, Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Chronic Lymphocytic Leukemia
Interim Data of Cirmtuzumab and Ibrutinib Show Efficacy in MCL and CLL
June 12, 2020
Hun Ju Lee, MD, discusses the clinical activity of cirmtuzumab, an anti-ROR1 antibody, in combination with ibrutinib in a phase 1b/2 study of patients with mantle cell lymphoma or chronic lymphocytic leukemia.
Ublituximab Plus Ibrutinib Induces Promises Responses in High-Risk Relapsed/Refractory CLL
June 11, 2020
In an interview with Targeted Oncology, Jeff P. Sharman, MD, discussed the findings for the combination of ublituximab plus ibrutinib as treatment of patients with high-risk relapsed/refractory chronic lymphocytic leukemia.
Cirmtuzumab Added to Ibrutinib Induces Responses in R/R MCL and CLL
June 06, 2020
Compelling objective responses and safety results were demonstrated with the combination of cirmtuzumab and ibrutinib in cohorts of patients with mantle cell lymphoma and chronic lymphocytic leukemia, who were treated in the phase 1b/2 clinical trial.
Long-term Data: Acalabrutinib Provides Tolerable, Durable Responses in Relapsed/Refractory CLL
May 18, 2020
Long-term data from a phase Ib/II trial of the BTK inhibitor acalabrutinib were recently published. Acalabrutinib appears to evoke durable responses with good safety and efficacy.
Tumor Mutational Load Can Help Fine-Tune Prognoses in CLL
May 18, 2020
Patients with chronic lymphocytic leukemia face uncertain futures, as clinicians can have a difficult time predicting whether and when a patient will need treatment. New research suggests tumor mutational load could be a helpful prognostic tool.
Expanding Options for Treatment of CLL Using BTK Inhibitors
May 08, 2020
Jennifer R. Brown, MD, PhD, and Alan Skarbnik, MD, describe the rationale for treating chronic lymphocytic leukemia with BTK inhibition, and explore current trends in data that impact treatment selection.
Acalabrutinib May Be A Safer Alternative to Ibrutinib in CLL
May 07, 2020
In an interview with Targeted Oncology, Lori A. Leslie, MD, discussed the importance of analyzing treatment outcomes in real-world patients with chronic lymphocytic leukemia compared with only reviewing data from clinical trials that do not represent all patients seen in the community setting.
Comparing Toxicity Profiles of Available Frontline Agents in CLL
May 05, 2020
Jennifer Woyach, MD, discusses the adverse events that differentiate the toxicity profiles of the treatments that are available in the frontline setting for patients with chronic lymphocytic leukemia.
U2 Regimen Improves PFS in Previously Treated and Relapsed/Refractory CLL Cohorts
May 05, 2020
"It’s extremely gratifying to see positive results for this important trial exploring the combination of umbralisib and ublituximab in patients with both front-line and relapsed/refractory CLL."
Follow-Up Shows Venetoclax Plus Rituximab has Long-Term Efficacy in CLL
April 28, 2020
Alexey V. Danilov, MD, PhD, discusses a treatment regimen of venetoclax plus rituximab used for patients with chronic lymphocytic leukemia the 2019 American Society of Hematology Annual Meeting.